更新于：2024-11-21

Hormone therapy(Orpharma Pty Ltd.)

更新于：2024-11-21

概要

研发状态

概要

基本信息

药物类型

激素

别名-

靶点-

作用机制-

治疗领域-

在研适应症-

非在研适应症-

原研机构

Orpharma Pty Ltd.

在研机构

Orpharma Pty Ltd.

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 Hormone therapy(Orpharma Pty Ltd.) 相关的临床结果

登录后查看更多信息

100 项与 Hormone therapy(Orpharma Pty Ltd.) 相关的转化医学

登录后查看更多信息

100 项与 Hormone therapy(Orpharma Pty Ltd.) 相关的专利（医药）

登录后查看更多信息

120

项与 Hormone therapy(Orpharma Pty Ltd.) 相关的文献（医药）

2024-09-05·Journal of Chest Surgery

Recurrence-Free Survival after Postoperative Hormone Therapy for Catamenial Pneumothorax

Article

作者: Woo, Won-Gi ; Jung, Yong-Ho ; Kim, Ji Hoon ; Lee, Sungsoo ; Moon, Duk Hwan

BackgroundCatamenial pneumothorax (CP) is a rare form of spontaneous pneumothorax that is linked to endometriosis; thus, it predominantly manifests in women of reproductive age. Considerable research has explored the potential benefits of postoperative hormone therapy following various surgical interventions. This study was performed to examine the clinical implications of postoperative hormone treatment in patients with CP.MethodsThe study included patients who underwent surgical intervention for CP between November 2009 and February 2023. These procedures included wedge resection, diaphragm resection, and total pleural coverage. Recurrence-free survival was analyzed using the Kaplan-Meier log-rank test to assess the impact of hormone therapy. Additionally, Cox proportional hazards analysis was employed to identify risk factors associated with postoperative CP recurrence.ResultsThe study included 41 patients, with a median age of 38.4 years. Among them, 27 individuals received hormone therapy, 8 of whom experienced recurrence during a median follow-up period of 1 year. Patients who received hormone therapy exhibited a lower rate of recurrence than those who did not; however, the difference was not statistically significant, likely due to the small sample size. Side effects of hormone therapy included depression (6.8%), excessive sweating (3.4%), and headache (3.4%). In the analysis of risk factors for postoperative recurrence, diaphragm resection emerged as a protective factor (hazard ratio, 0.16; 95% confidence interval, 0.03-0.77; p=0.022).ConclusionHormone treatment combined with surgery did not significantly impact recurrence in patients with CP. The application of diaphragm resection was the sole factor that displayed significance in preventing CP recurrence.

2024-08-01·Zhongguo shi yan xue ye xue za zhi

[Etiology, Clinical Characteristics and Prognosis of Secondary Hemophagocytic Syndrome].

Article

作者: Xing, Xiao-Ying ; Hao, Jing-Nan ; Qiao, Shu-Kai ; Sun, Meng-Meng ; Zhang, Ya-Li

题目继发性噬血细胞综合征病因、临床特点及预后分析.目的了解继发性噬血细胞综合征（HLH）的病因、临床特征及预后，以提高对HLH的认识，减少临床HLH的误诊和漏诊率。.方法收集2015年1月至2021年12月经本院收治的75例成人继发性HLH患者的病历资料，对其病因、临床特点、实验室检查结果、治疗及预后等进行回顾性分析。随访至末次出院时间。.结果75例患者中，感染相关HLH最常见（45.33%），其次为淋巴瘤相关HLH（17.33%）。临床表现以发热最为常见（97.67%），实验室指标中NK细胞活性（98.31%降低）、sCD25浓度（93.22%升高）、血清铁蛋白（94.44%升高）在诊断中灵敏度更高。将不同病因HLH患者初诊时临床表现及实验室指标进行比较，性别、淋巴结肿大、骨髓形态是否可见噬血现象对原发病的诊断更有价值（均 P <0.05）。将不同病因HLH患者的治疗方案与临床转归进行比较，自身免疫性疾病相关HLH采用激素+环孢素治疗临床缓解率最高（83.3%）（P <0.05）。患者总体12个月的生存率为26.7%，其中感染相关HLH患者12个月的生存率最低（14.7%），自身免疫性疾病相关HLH患者12个月的生存率最高（63.6%）。.结论成人继发性HLH病因和临床特点多样，预后凶险，病情严重程度具有异质性，早期明确病因对HLH预后具有重要意义，需要进一步提高对HLH的认识。.

2024-02-01·Menopause

Does hormone therapy exacerbate other venous thromboembolism risk factors?

Article

作者: Wilkinson, Gregg ; Weller, Susan C. ; Porterfield, Laura ; Chen, Lu ; Davis, John W.

AbstractObjectivePostmenopausal symptoms in women at higher risk for venous thromboembolism (VTE) due to comorbidities are often undertreated because of concerns that hormone therapy (HT) may increase VTE risk; however, it is unclear how much HT impacts risk of VTE when compared with other risk factors.MethodsThis is a case-control study in a commercial claims database from 2007 to 2019. Women aged 50 to 64 years (n = 223,949) were classified as cases if they had an International Classification of Diseases code indicating an acute VTE plus a filled prescription for an anticoagulant, placement of intravascular vena cava filter, or death within 30 days of diagnosis. Controls were matched 10:1 to each case by index date and age. Risk factors and comorbidities present within the year before index were examined. Exposure was defined as a HT prescription within 60 days before index.ResultsThere were 20,359 VTE cases and 203,590 matched controls. A conditional logistic regression indicated that the greatest risks for VTE were from metastatic cancer (odds ratio [OR], 13.66; 95% CI, 12.64-14.75), hospitalization/surgery (OR, 8.51; 95% CI, 8.09-8.96), trauma (OR, 3.52; 95% CI, 3.32-3.73), comorbidity burden (OR, 3.51; 95% CI, 3.34-3.69), history of hypercoagulable condition (OR, 3.10; 95% CI, 2.87-3.36), and varicose veins (OR, 2.87; 95% CI, 2.56-3.22). Regarding hormone exposure, we observed ORs of 1.51 (95% CI, 1.43-1.60) for any recent hormone exposure; 1.13 (95% CI, 1.04-1.23; number needed to harm, 4,274) for unopposed estrogen menopausal HT; 1.23 (95% CI, 1.10-1.38; number needed to harm, 2,440) for combined menopausal HT; and 5.22 (95% CI, 4.67-5.84) for combined hormonal contraceptives compared with no recent HT exposure.ConclusionsHormone therapy exposure did not appear to adversely influence other risk factors, and exposure generally played a minor role in VTE risk. Contraceptives, however, were a strong risk factor.

100 项与 Hormone therapy(Orpharma Pty Ltd.) 相关的药物交易

登录后查看更多信息

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESMO2021	N/A	转移性乳腺癌一线	112	Palbociclib + hormone-therapy alone	(齋糧構鹽鹹淵糧淵觸範) = 鬱糧壓顧淵壓網衊醖餘觸製鑰製餘觸鑰繭繭蓋 (鹹窪衊壓鏇廠鹹夢窪構 )	-	2021-09-16
				Concomitant PPIs	(齋糧構鹽鹹淵糧淵觸範) = 鬱鹽網選獵構鬱顧網網觸製鑰製餘觸鑰繭繭蓋 (鹹窪衊壓鏇廠鹹夢窪構 )